On 07 April 2016, Dr. Falk Pharma Gmbh, a pharmaceutical company based in Germany that specializes in the development and sales of medication for indications in hepatology and gastroenterology, appointed Estrebillo Law Office as its agent and attorney in fact in the Philippines, in relation to its petition for renewal of registration of the following trademarks: BUDENOFALK, DR. FALK (DEVICE), SALOFALK and URSOFALK. The Intellectual Property Office of the Philippines was formally notified of the said appointment on 28 April 2016.
Dr. Falk Pharma GmbH is an independent family firm based in Freiburg im Breigau, Germany. Its innovative drugs for bowel and liver diseases are sold in 61 countries, including the Philippines. The company’s pharmaceuticals are used for successfully treating inflammatory bowel disease, cholestatic liver disease, irritable bowel syndrome, and constipation, as well as for colon cleansing prior to colonoscopies.
In 1974, the company launched Chenofalk®, the first ever bile acid for the medicinal dissolution of gall-bladder stones. This was followed by the second bile acid preparation, Ursofalk®, which is still the leading medication for the treatment of cholestatic liver diseases today. In 1984, the company brought out Salofalk®, the world’s first mesalazine preparation for treating inflammatory bowel diseases. In 1998, it added to its wide range of products for the treatment of inflammatory bowel disease Budenofalk®, a corticosteroid product for topical action.
Dr. Falk Pharma Gmbh first appointed Estrebillo Law Office as its agent or representative and attorney in fact, in relation to its existing Letters Patent and Certificates of Registration, as well as new patent and trademark applications in the Philippines, in the year 2011.